Tislelizumab is an anti-PD-1 antibody that, in the phase III randomized RATIONALE-301trial, demonstrated noninferior overall survival (OS) benefit to sorafenib30, and has been approved in China as both the first-line and the second-line treatment for patients with unresectable HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.